ForPatients

by Roche

Age-Related Macular Degeneration

An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration

Trial Status Trial Runs In Trial Identifier

Recruiting 7 Countries NCT05300724 2022-000046-15

GE43220

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a multicenter prospective study in participants with intermediate age-related macular degeneration (iAMD). One primary objective of this study is to assess iAMD disease progression, by the timeline and rates of conversion for high-risk iAMD at baseline to more advanced atrophic AMD stages. The other primary objective of this observational study is to assess the feasibility of measuring the rate of photoreceptor loss as a potential clinical endpoint. The study will consist of an observation period of approximately 3 years (~144 weeks) for participants.

Genentech, Inc. Sponsor			
NCT05300724 2022-00004 Trial Identifiers	96-15 GE43220		
Eligibility Criteria:			
Gender All	Age >=50 Years & <= 94 Years	Healthy Volunteers	